ProShare Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$555K Buy
7,390
+236
+3% +$18.6K ﹤0.01% 1004
2025
Q4
$566K Buy
7,154
+1,476
+26% +$111K ﹤0.01% 1066
2025
Q3
$371K Sell
5,678
-265
-4% -$12.9K ﹤0.01% 1283
2025
Q2
$235K Sell
5,943
-1,228
-17% -$40.2K ﹤0.01% 1614
2025
Q1
$216K Sell
7,171
-309
-4% -$10.1K ﹤0.01% 1640
2024
Q4
$262K Sell
7,480
-1,160
-13% -$43.4K ﹤0.01% 1740
2024
Q3
$346K Sell
8,640
-371
-4% -$17.3K ﹤0.01% 1367
2024
Q2
$429K Sell
9,011
-1,205
-12% -$49.4K ﹤0.01% 1057
2024
Q1
$443K Buy
10,216
+1,049
+11% +$50K ﹤0.01% 1162
2023
Q4
$464K Sell
9,167
-203
-2% -$9.72K ﹤0.01% 1081
2023
Q3
$425K Buy
9,370
+112
+1% +$4.62K ﹤0.01% 994
2023
Q2
$380K Sell
9,258
-653
-7% -$25.1K ﹤0.01% 1120
2023
Q1
$354K Sell
9,911
-3,992
-29% -$150K ﹤0.01% 1105
2022
Q4
$525K Sell
13,903
-295
-2% -$12.4K ﹤0.01% 943
2022
Q3
$628K Buy
14,198
+831
+6% +$35K ﹤0.01% 833
2022
Q2
$495K Sell
13,367
-4,534
-25% -$171K ﹤0.01% 939
2022
Q1
$663K Sell
17,901
-5,531
-24% -$181K ﹤0.01% 1112
2021
Q4
$713K Sell
23,432
-10,067
-30% -$317K ﹤0.01% 1224
2021
Q3
$1.12M Buy
33,499
+3,076
+10% +$116K ﹤0.01% 862
2021
Q2
$1.21M Buy
30,423
+8,288
+37% +$325K ﹤0.01% 926
2021
Q1
$995K Sell
22,135
-1,955
-8% -$109K ﹤0.01% 985
2020
Q4
$1.36M Sell
24,090
-839
-3% -$41.8K 0.01% 756
2020
Q3
$1.18M Buy
24,929
+620
+3% +$34.4K 0.01% 679
2020
Q2
$1.43M Buy
24,309
+2,602
+12% +$145K 0.01% 621
2020
Q1
$1.03M Sell
21,707
-11,769
-35% -$656K 0.01% 593
2019
Q4
$2.02M Sell
33,476
-7,564
-18% -$451K 0.01% 621
2019
Q3
$2.46M Sell
41,040
-3,341
-8% -$218K 0.01% 549
2019
Q2
$2.85M Sell
44,381
-7,907
-15% -$559K 0.02% 517
2019
Q1
$4.24M Buy
52,288
+1,613
+3% +$104K 0.03% 447
2018
Q4
$2.74M Sell
50,675
-10,154
-17% -$518K 0.02% 511
2018
Q3
$3.14M Buy
60,829
+5,086
+9% +$239K 0.02% 523
2018
Q2
$2.32M Sell
55,743
-5,436
-9% -$241K 0.02% 588
2018
Q1
$2.7M Sell
61,179
-9,419
-13% -$479K 0.02% 559
2017
Q4
$3.55M Sell
70,598
-2,407
-3% -$132K 0.02% 500
2017
Q3
$3.7M Buy
73,005
+6,775
+10% +$355K 0.03% 434
2017
Q2
$3.37M Sell
66,230
-1,039
-2% -$48.4K 0.03% 445
2017
Q1
$2.7M Sell
67,269
-14,539
-18% -$653K 0.03% 474
2016
Q4
$3.91M Buy
81,808
+2,221
+3% +$87.9K 0.04% 383
2016
Q3
$2.92M Sell
79,587
-14,326
-15% -$448K 0.04% 386
2016
Q2
$2.19M Buy
93,913
+1,997
+2% +$64.4K 0.03% 473
2016
Q1
$3.72M Sell
91,916
-9,179
-9% -$373K 0.05% 300
2015
Q4
$6.26M Buy
101,095
+5,208
+5% +$281K 0.08% 254
2015
Q3
$3.88M Sell
95,887
-6,291
-6% -$326K 0.05% 316
2015
Q2
$5.88M Sell
102,178
-21,857
-18% -$1.39M 0.08% 243
2015
Q1
$7.9M Buy
124,035
+14,495
+13% +$983K 0.09% 222
2014
Q4
$6.76M Sell
109,540
-1,589
-1% -$78.4K 0.08% 262
2014
Q3
$4.32M Sell
111,129
-22,086
-17% -$783K 0.06% 327
2014
Q2
$4.59M Sell
133,215
-73,546
-36% -$2.32M 0.06% 327
2014
Q1
$8.93M Buy
206,761
+143,767
+228% +$6.97M 0.11% 155
2013
Q4
$2.51M Sell
62,994
-51,471
-45% -$1.83M 0.04% 626
2013
Q3
$4.3M Buy
114,465
+17,563
+18% +$525K 0.1% 161
2013
Q2
$2.6M Buy
+96,902
New +$2.06M 0.05% 361

Other funds holding IONS

ProShare Advisors's IONS Position: Q1 2026 in Review

ProShare Advisors increased its Ionis Pharmaceuticals (IONS) stake by 3.3% in Q1 2026, buying an estimated $18.6K and bringing the position to 7,390 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

ProShare Advisors first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.93M in Q1 2014. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • ProShare Advisors held 7,390 shares of Ionis Pharmaceuticals worth $555K as of Q1 2026.
  • ProShare Advisors bought 236 Ionis Pharmaceuticals shares in Q1 2026, an estimated $18.6K.
  • Ionis Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1004 holding.
  • ProShare Advisors first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • ProShare Advisors's Ionis Pharmaceuticals position peaked at $8.93M in Q1 2014.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.